| Hematopoietic and Lymphatic System Neoplasm altered in cohorts of …ALTERED_INderived200 of 397show all (up to 200) |
|---|
| ← altered in cohorts of | IGHV2-70 437 / 961 cases (45 %) · ssm · MMRF-COMMPASS · largest of 2 cohorts | — | — | Multiple Myeloma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | DDX3X 124 / 297 cases (42 %) · ssm · mbn_sfu_2023 | — | — | B-Cell Non-Hodgkin Lymphoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | IGLV3-1 364 / 961 cases (38 %) · ssm · MMRF-COMMPASS · largest of 2 cohorts | — | — | Multiple Myeloma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | FLT3 278 / 903 cases (31 %) · ssm · aml_ohsu_2022 · largest of 7 cohorts | — | — | Acute Myeloid Leukemia | 7 | Observed | cbioportal | graph → |
| ← altered in cohorts of | SHCBP1 73 / 263 cases (28 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NPM1 233 / 903 cases (26 %) · ssm · aml_ohsu_2022 · largest of 7 cohorts | — | — | Acute Myeloid Leukemia | 7 | Observed | cbioportal | graph → |
| ← altered in cohorts of | VPS35 67 / 263 cases (25 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ORC6 66 / 263 cases (25 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TPTE 66 / 263 cases (25 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | IGHV2-70D 238 / 961 cases (25 %) · ssm · MMRF-COMMPASS · largest of 2 cohorts | — | — | Multiple Myeloma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | KMT2D 247 / 1,001 cases (25 %) · ssm · dlbcl_duke_2017 · largest of 5 cohorts | — | — | Diffuse Large B-Cell Lymphoma Unclassifiable | 5 | Observed | cbioportal | graph → |
| ← altered in cohorts of | KRAS 227 / 961 cases (24 %) · ssm · MMRF-COMMPASS · largest of 4 cohorts | — | — | Multiple Myeloma | 4 | Observed | gdc | graph → |
| ← altered in cohorts of | MYLK3 62 / 263 cases (24 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CNTNAP3B 70 / 297 cases (24 %) · ssm · mbn_sfu_2023 | — | — | B-Cell Non-Hodgkin Lymphoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | BCL7A 212 / 961 cases (22 %) · ssm · MMRF-COMMPASS · largest of 3 cohorts | — | — | Multiple Myeloma | 3 | Observed | gdc | graph → |
| ← altered in cohorts of | IGLL5 211 / 961 cases (22 %) · ssm · MMRF-COMMPASS · largest of 3 cohorts | — | — | Multiple Myeloma | 3 | Observed | gdc | graph → |
| ← altered in cohorts of | DNMT3A 197 / 903 cases (22 %) · ssm · aml_ohsu_2022 · largest of 5 cohorts | — | — | Acute Myeloid Leukemia | 5 | Observed | cbioportal | graph → |
| ← altered in cohorts of | C16orf87 56 / 263 cases (21 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LTB 186 / 961 cases (19 %) · ssm · MMRF-COMMPASS · largest of 2 cohorts | — | — | Multiple Myeloma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | NRAS 183 / 961 cases (19 %) · ssm · MMRF-COMMPASS · largest of 7 cohorts | — | — | Multiple Myeloma | 7 | Observed | gdc | graph → |
| ← altered in cohorts of | PTPRC 50 / 263 cases (19 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TTN 181 / 961 cases (19 %) · ssm · MMRF-COMMPASS · largest of 2 cohorts | — | — | Multiple Myeloma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | GARIN4 55 / 297 cases (19 %) · ssm · mbn_sfu_2023 | — | — | B-Cell Non-Hodgkin Lymphoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | ZNF280B 48 / 263 cases (18 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ZNF280A 47 / 263 cases (18 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FBXO11 53 / 297 cases (18 %) · ssm · mbn_sfu_2023 | — | — | B-Cell Non-Hodgkin Lymphoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | GGTLC2 46 / 263 cases (17 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PRAME 46 / 263 cases (17 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MYD88 172 / 1,001 cases (17 %) · ssm · dlbcl_duke_2017 · largest of 4 cohorts | — | — | Diffuse Large B-Cell Lymphoma Unclassifiable | 4 | Observed | cbioportal | graph → |
| ← altered in cohorts of | BTG1 67 / 396 cases (17 %) · ssm · mbn_msk_2024 · largest of 2 cohorts | — | — | B-Cell Non-Hodgkin Lymphoma | 2 | Observed | cbioportal | graph → |
| ← altered in cohorts of | OR11H12 44 / 263 cases (17 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GP6 49 / 297 cases (16 %) · ssm · mbn_sfu_2023 | — | — | B-Cell Non-Hodgkin Lymphoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | ATP6V1G3 43 / 263 cases (16 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SLAMF6 43 / 263 cases (16 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NEB 123 / 755 cases (16 %) · ssm · mbn_mdacc_2013 | — | — | B-Cell Non-Hodgkin Lymphoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | AKAP10 47 / 297 cases (16 %) · ssm · mbn_sfu_2023 | — | — | B-Cell Non-Hodgkin Lymphoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | MAP3K9 47 / 297 cases (16 %) · ssm · mbn_sfu_2023 | — | — | B-Cell Non-Hodgkin Lymphoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | CD84 40 / 263 cases (15 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ENSA 40 / 263 cases (15 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MIR5195 143 / 961 cases (15 %) · ssm · MMRF-COMMPASS | — | — | Multiple Myeloma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ADAMTSL4 39 / 263 cases (15 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | C1orf56 39 / 263 cases (15 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CD48 39 / 263 cases (15 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CDC42SE1 39 / 263 cases (15 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GABPB2 39 / 263 cases (15 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GOLPH3L 39 / 263 cases (15 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MLLT11 39 / 263 cases (15 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TARS2 39 / 263 cases (15 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PIM1 147 / 1,001 cases (15 %) · ssm · dlbcl_duke_2017 · largest of 4 cohorts | — | — | Diffuse Large B-Cell Lymphoma Unclassifiable | 4 | Observed | cbioportal | graph → |
| ← altered in cohorts of | VIPR2 29 / 200 cases (14 %) · ssm · TCGA-LAML | — | — | Acute Myeloid Leukemia | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ANXA9 38 / 263 cases (14 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ARNT 38 / 263 cases (14 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | BNIPL 38 / 263 cases (14 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CTSK 38 / 263 cases (14 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CTSS 38 / 263 cases (14 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CTXND2 38 / 263 cases (14 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ECM1 38 / 263 cases (14 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FAM243B 38 / 263 cases (14 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | HORMAD1 38 / 263 cases (14 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | KCNE1B 38 / 263 cases (14 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MCL1 38 / 263 cases (14 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MINDY1 38 / 263 cases (14 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PRUNE1 38 / 263 cases (14 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SLAMF1 38 / 263 cases (14 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SLAMF7 38 / 263 cases (14 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SMIM11B 38 / 263 cases (14 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SMIM34B 38 / 263 cases (14 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FRG2C 42 / 297 cases (14 %) · ssm · mbn_sfu_2023 | — | — | B-Cell Non-Hodgkin Lymphoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | SMPD1 42 / 297 cases (14 %) · ssm · mbn_sfu_2023 | — | — | B-Cell Non-Hodgkin Lymphoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | SPATA31A6 42 / 297 cases (14 %) · ssm · mbn_sfu_2023 | — | — | B-Cell Non-Hodgkin Lymphoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | ZNF701 42 / 297 cases (14 %) · ssm · mbn_sfu_2023 | — | — | B-Cell Non-Hodgkin Lymphoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | CERS2 37 / 263 cases (14 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GPT2 37 / 263 cases (14 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LYSMD1 37 / 263 cases (14 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RPRD2 37 / 263 cases (14 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SCNM1 37 / 263 cases (14 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SEMA6C 37 / 263 cases (14 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SETDB1 37 / 263 cases (14 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TMOD4 37 / 263 cases (14 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TNFAIP8L2 37 / 263 cases (14 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | VANGL2 37 / 263 cases (14 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | VPS72 37 / 263 cases (14 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | HLA-A 55 / 396 cases (14 %) · ssm · mbn_msk_2024 | — | — | B-Cell Non-Hodgkin Lymphoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | L1TD1 41 / 297 cases (14 %) · ssm · mbn_sfu_2023 | — | — | B-Cell Non-Hodgkin Lymphoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | FCRL4 36 / 263 cases (14 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NEK7 36 / 263 cases (14 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PIP5K1A 36 / 263 cases (14 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PRPF3 36 / 263 cases (14 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CD79B 54 / 396 cases (14 %) · ssm · mbn_msk_2024 · largest of 2 cohorts | — | — | B-Cell Non-Hodgkin Lymphoma | 2 | Observed | cbioportal | graph → |
| ← altered in cohorts of | C8orf33 27 / 200 cases (14 %) · ssm · TCGA-LAML | — | — | Acute Myeloid Leukemia | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | COMMD5 27 / 200 cases (14 %) · ssm · TCGA-LAML | — | — | Acute Myeloid Leukemia | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DLGAP2 27 / 200 cases (14 %) · ssm · TCGA-LAML | — | — | Acute Myeloid Leukemia | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RPL8 27 / 200 cases (14 %) · ssm · TCGA-LAML | — | — | Acute Myeloid Leukemia | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ZNF16 27 / 200 cases (14 %) · ssm · TCGA-LAML | — | — | Acute Myeloid Leukemia | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ZNF250 27 / 200 cases (14 %) · ssm · TCGA-LAML | — | — | Acute Myeloid Leukemia | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ZNF517 27 / 200 cases (14 %) · ssm · TCGA-LAML | — | — | Acute Myeloid Leukemia | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ZNF7 27 / 200 cases (14 %) · ssm · TCGA-LAML | — | — | Acute Myeloid Leukemia | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | APH1A 35 / 263 cases (13 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | C1orf54 35 / 263 cases (13 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CA14 35 / 263 cases (13 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CIART 35 / 263 cases (13 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FCRL1 35 / 263 cases (13 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FCRL2 35 / 263 cases (13 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FCRL3 35 / 263 cases (13 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FCRL5 35 / 263 cases (13 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MRPS21 35 / 263 cases (13 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NCSTN 35 / 263 cases (13 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NHLH1 35 / 263 cases (13 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SERPINC1 35 / 263 cases (13 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SYT11 35 / 263 cases (13 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | COL22A1 26 / 200 cases (13 %) · ssm · TCGA-LAML | — | — | Acute Myeloid Leukemia | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CYC1 26 / 200 cases (13 %) · ssm · TCGA-LAML | — | — | Acute Myeloid Leukemia | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DYNC2I1 26 / 200 cases (13 %) · ssm · TCGA-LAML | — | — | Acute Myeloid Leukemia | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ERICH1 26 / 200 cases (13 %) · ssm · TCGA-LAML | — | — | Acute Myeloid Leukemia | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FBXO25 26 / 200 cases (13 %) · ssm · TCGA-LAML | — | — | Acute Myeloid Leukemia | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LY6D 26 / 200 cases (13 %) · ssm · TCGA-LAML | — | — | Acute Myeloid Leukemia | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LY6K 26 / 200 cases (13 %) · ssm · TCGA-LAML | — | — | Acute Myeloid Leukemia | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LYNX1 26 / 200 cases (13 %) · ssm · TCGA-LAML | — | — | Acute Myeloid Leukemia | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LYNX1-SLURP2 26 / 200 cases (13 %) · ssm · TCGA-LAML | — | — | Acute Myeloid Leukemia | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LYPD2 26 / 200 cases (13 %) · ssm · TCGA-LAML | — | — | Acute Myeloid Leukemia | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | OR4F21 26 / 200 cases (13 %) · ssm · TCGA-LAML | — | — | Acute Myeloid Leukemia | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PSCA 26 / 200 cases (13 %) · ssm · TCGA-LAML | — | — | Acute Myeloid Leukemia | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PUF60 26 / 200 cases (13 %) · ssm · TCGA-LAML | — | — | Acute Myeloid Leukemia | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SLURP1 26 / 200 cases (13 %) · ssm · TCGA-LAML | — | — | Acute Myeloid Leukemia | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SLURP2 26 / 200 cases (13 %) · ssm · TCGA-LAML | — | — | Acute Myeloid Leukemia | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TDRP 26 / 200 cases (13 %) · ssm · TCGA-LAML | — | — | Acute Myeloid Leukemia | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TG 26 / 200 cases (13 %) · ssm · TCGA-LAML | — | — | Acute Myeloid Leukemia | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | THEM6 26 / 200 cases (13 %) · ssm · TCGA-LAML | — | — | Acute Myeloid Leukemia | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TRPV5 26 / 200 cases (13 %) · ssm · TCGA-LAML | — | — | Acute Myeloid Leukemia | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ZNF34 26 / 200 cases (13 %) · ssm · TCGA-LAML | — | — | Acute Myeloid Leukemia | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ZNF596 26 / 200 cases (13 %) · ssm · TCGA-LAML | — | — | Acute Myeloid Leukemia | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ZNF783 26 / 200 cases (13 %) · ssm · TCGA-LAML | — | — | Acute Myeloid Leukemia | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GPR52 34 / 263 cases (13 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RABGAP1L 34 / 263 cases (13 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RC3H1 34 / 263 cases (13 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LRRC4B 38 / 297 cases (13 %) · ssm · mbn_sfu_2023 | — | — | B-Cell Non-Hodgkin Lymphoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | ANP32E 33 / 263 cases (13 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CD5L 33 / 263 cases (13 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | COPA 33 / 263 cases (13 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DARS2 33 / 263 cases (13 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GON4L 33 / 263 cases (13 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PGM5 33 / 263 cases (13 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PSMD4 33 / 263 cases (13 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ZBTB37 33 / 263 cases (13 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ABCF2 25 / 200 cases (13 %) · ssm · TCGA-LAML | — | — | Acute Myeloid Leukemia | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ADCY8 25 / 200 cases (13 %) · ssm · TCGA-LAML | — | — | Acute Myeloid Leukemia | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ADGRB1 25 / 200 cases (13 %) · ssm · TCGA-LAML | — | — | Acute Myeloid Leukemia | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | AGO2 25 / 200 cases (13 %) · ssm · TCGA-LAML | — | — | Acute Myeloid Leukemia | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ARC 25 / 200 cases (13 %) · ssm · TCGA-LAML | — | — | Acute Myeloid Leukemia | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ARHGAP39 25 / 200 cases (13 %) · ssm · TCGA-LAML | — | — | Acute Myeloid Leukemia | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ARMC1 25 / 200 cases (13 %) · ssm · TCGA-LAML | — | — | Acute Myeloid Leukemia | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ASAP1 25 / 200 cases (13 %) · ssm · TCGA-LAML | — | — | Acute Myeloid Leukemia | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | BOP1 25 / 200 cases (13 %) · ssm · TCGA-LAML | — | — | Acute Myeloid Leukemia | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CCN4 25 / 200 cases (13 %) · ssm · TCGA-LAML | — | — | Acute Myeloid Leukemia | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CYP11B1 25 / 200 cases (13 %) · ssm · TCGA-LAML | — | — | Acute Myeloid Leukemia | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CYP11B2 25 / 200 cases (13 %) · ssm · TCGA-LAML | — | — | Acute Myeloid Leukemia | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | EEF1D 25 / 200 cases (13 %) · ssm · TCGA-LAML | — | — | Acute Myeloid Leukemia | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | EFR3A 25 / 200 cases (13 %) · ssm · TCGA-LAML | — | — | Acute Myeloid Leukemia | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ESYT2 25 / 200 cases (13 %) · ssm · TCGA-LAML | — | — | Acute Myeloid Leukemia | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | EXOSC4 25 / 200 cases (13 %) · ssm · TCGA-LAML | — | — | Acute Myeloid Leukemia | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GALNTL5 25 / 200 cases (13 %) · ssm · TCGA-LAML | — | — | Acute Myeloid Leukemia | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GBX1 25 / 200 cases (13 %) · ssm · TCGA-LAML | — | — | Acute Myeloid Leukemia | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GIMAP8 25 / 200 cases (13 %) · ssm · TCGA-LAML | — | — | Acute Myeloid Leukemia | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GLI4 25 / 200 cases (13 %) · ssm · TCGA-LAML | — | — | Acute Myeloid Leukemia | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GML 25 / 200 cases (13 %) · ssm · TCGA-LAML | — | — | Acute Myeloid Leukemia | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GPAA1 25 / 200 cases (13 %) · ssm · TCGA-LAML | — | — | Acute Myeloid Leukemia | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GPR20 25 / 200 cases (13 %) · ssm · TCGA-LAML | — | — | Acute Myeloid Leukemia | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GRINA 25 / 200 cases (13 %) · ssm · TCGA-LAML | — | — | Acute Myeloid Leukemia | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GSDMC 25 / 200 cases (13 %) · ssm · TCGA-LAML | — | — | Acute Myeloid Leukemia | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | HHLA1 25 / 200 cases (13 %) · ssm · TCGA-LAML | — | — | Acute Myeloid Leukemia | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | HSF1 25 / 200 cases (13 %) · ssm · TCGA-LAML | — | — | Acute Myeloid Leukemia | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | HTR5A 25 / 200 cases (13 %) · ssm · TCGA-LAML | — | — | Acute Myeloid Leukemia | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | JRK 25 / 200 cases (13 %) · ssm · TCGA-LAML | — | — | Acute Myeloid Leukemia | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | KCNH2 25 / 200 cases (13 %) · ssm · TCGA-LAML | — | — | Acute Myeloid Leukemia | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | KCNK9 25 / 200 cases (13 %) · ssm · TCGA-LAML | — | — | Acute Myeloid Leukemia | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | KCNQ3 25 / 200 cases (13 %) · ssm · TCGA-LAML | — | — | Acute Myeloid Leukemia | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | KHDRBS3 25 / 200 cases (13 %) · ssm · TCGA-LAML | — | — | Acute Myeloid Leukemia | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LRRC14 25 / 200 cases (13 %) · ssm · TCGA-LAML | — | — | Acute Myeloid Leukemia | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LY6E 25 / 200 cases (13 %) · ssm · TCGA-LAML | — | — | Acute Myeloid Leukemia | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LY6H 25 / 200 cases (13 %) · ssm · TCGA-LAML | — | — | Acute Myeloid Leukemia | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MAF1 25 / 200 cases (13 %) · ssm · TCGA-LAML | — | — | Acute Myeloid Leukemia | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MFSD3 25 / 200 cases (13 %) · ssm · TCGA-LAML | — | — | Acute Myeloid Leukemia | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MROH1 25 / 200 cases (13 %) · ssm · TCGA-LAML | — | — | Acute Myeloid Leukemia | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MROH6 25 / 200 cases (13 %) · ssm · TCGA-LAML | — | — | Acute Myeloid Leukemia | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NAPRT 25 / 200 cases (13 %) · ssm · TCGA-LAML | — | — | Acute Myeloid Leukemia | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NDRG1 25 / 200 cases (13 %) · ssm · TCGA-LAML | — | — | Acute Myeloid Leukemia | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NRBP2 25 / 200 cases (13 %) · ssm · TCGA-LAML | — | — | Acute Myeloid Leukemia | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NSMCE2 25 / 200 cases (13 %) · ssm · TCGA-LAML | — | — | Acute Myeloid Leukemia | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | OPRK1 25 / 200 cases (13 %) · ssm · TCGA-LAML | — | — | Acute Myeloid Leukemia | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PHF20L1 25 / 200 cases (13 %) · ssm · TCGA-LAML | — | — | Acute Myeloid Leukemia | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | POU5F1B 25 / 200 cases (13 %) · ssm · TCGA-LAML | — | — | Acute Myeloid Leukemia | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PPP1R16A 25 / 200 cases (13 %) · ssm · TCGA-LAML | — | — | Acute Myeloid Leukemia | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PTP4A3 25 / 200 cases (13 %) · ssm · TCGA-LAML | — | — | Acute Myeloid Leukemia | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PYCR3 25 / 200 cases (13 %) · ssm · TCGA-LAML | — | — | Acute Myeloid Leukemia | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | REPIN1 25 / 200 cases (13 %) · ssm · TCGA-LAML | — | — | Acute Myeloid Leukemia | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RHPN1 25 / 200 cases (13 %) · ssm · TCGA-LAML | — | — | Acute Myeloid Leukemia | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SCRIB 25 / 200 cases (13 %) · ssm · TCGA-LAML | — | — | Acute Myeloid Leukemia | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SHARPIN 25 / 200 cases (13 %) · ssm · TCGA-LAML | — | — | Acute Myeloid Leukemia | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SLC45A4 25 / 200 cases (13 %) · ssm · TCGA-LAML | — | — | Acute Myeloid Leukemia | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TRAPPC9 25 / 200 cases (13 %) · ssm · TCGA-LAML | — | — | Acute Myeloid Leukemia | 1 | Observed | gdc | graph → |